Celldex Therapeutics Book Value Per Share Growth & History (CLDX)
Celldex Therapeutics's book value per share was $7.92 for fiscal 2025.
View full Celldex Therapeutics company overviewCelldex Therapeutics annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.92 | -$3.33 | −29.61% |
| 2024 | 2024-12-31 | $11.25 | $3.57 | +46.55% |
| 2023 | 2023-12-31 | $7.68 | $0.77 | +11.12% |
| 2022 | 2022-12-31 | $6.91 | -$2.07 | −23.01% |
| 2021 | 2021-12-31 | $8.98 | $3.69 | +69.81% |
| 2020 | 2020-12-31 | $5.29 | -$0.25 | −4.58% |
| 2019 | 2019-12-31 | $5.54 | -$4.83 | −46.60% |
| 2018 | 2018-12-31 | $10.37 | -$15.22 | −59.47% |
| 2017 | 2017-12-31 | $25.60 | -$467.49 | −94.81% |
| 2016 | 2016-12-31 | $493.08 | -$165.06 | −25.08% |
| 2015 | 2015-12-31 | $658.14 | $129.23 | +24.43% |
| 2014 | 2014-12-31 | $528.91 | -$273.31 | −34.07% |
| 2013 | 2013-12-31 | $802.22 | $469.06 | +140.79% |
| 2012 | 2012-12-31 | $333.16 | -$14.85 | −4.27% |
| 2011 | 2011-12-31 | $348.01 | -$177.59 | −33.79% |
| 2010 | 2010-12-31 | $525.59 | -$307.53 | −36.91% |
| 2009 | 2009-12-31 | $833.12 | — | — |
Celldex Therapeutics quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $9.10 | -$0.77 | −7.79% |
| Q1 2026 | 2026-03-31 | $6.85 | -$3.74 | −35.28% |
| Q4 2025 | 2025-12-31 | $7.92 | -$3.33 | −29.61% |
| Q3 2025 | 2025-09-30 | $9.01 | -$2.84 | −23.98% |
| Q2 2025 | 2025-06-30 | $9.87 | -$2.40 | −19.59% |
| Q1 2025 | 2025-03-31 | $10.59 | -$2.13 | −16.77% |
| Q4 2024 | 2024-12-31 | $11.25 | $3.57 | +46.55% |
| Q3 2024 | 2024-09-30 | $11.85 | $6.63 | +126.93% |
| Q2 2024 | 2024-06-30 | $12.28 | $6.40 | +109.01% |
| Q1 2024 | 2024-03-31 | $12.72 | $6.32 | +98.56% |
| Q4 2023 | 2023-12-31 | $7.68 | $0.77 | +11.12% |
| Q3 2023 | 2023-09-30 | $5.22 | -$2.11 | −28.83% |
| Q2 2023 | 2023-06-30 | $5.87 | -$1.93 | −24.77% |
| Q1 2023 | 2023-03-31 | $6.41 | -$2.11 | −24.74% |
| Q4 2022 | 2022-12-31 | $6.91 | -$2.07 | −23.01% |
| Q3 2022 | 2022-09-30 | $7.33 | -$2.02 | −21.63% |
| Q2 2022 | 2022-06-30 | $7.81 | $3.21 | +69.68% |
| Q1 2022 | 2022-03-31 | $8.51 | $3.61 | +73.72% |
| Q4 2021 | 2021-12-31 | $8.98 | $3.69 | +69.81% |
| Q3 2021 | 2021-09-30 | $9.36 | $3.55 | +61.00% |
| Q2 2021 | 2021-06-30 | $4.60 | -$1.50 | −24.56% |
| Q1 2021 | 2021-03-31 | $4.90 | $0.18 | +3.83% |
| Q4 2020 | 2020-12-31 | $5.29 | -$0.25 | −4.58% |
| Q3 2020 | 2020-09-30 | $5.81 | -$0.56 | −8.81% |
| Q2 2020 | 2020-06-30 | $6.10 | -$1.30 | −17.56% |
| Q1 2020 | 2020-03-31 | $4.72 | -$4.05 | −46.19% |
| Q4 2019 | 2019-12-31 | $5.54 | -$4.83 | −46.60% |
| Q3 2019 | 2019-09-30 | $6.37 | -$163.80 | −96.25% |
| Q2 2019 | 2019-06-30 | $7.40 | -$175.61 | −95.96% |
| Q1 2019 | 2019-03-31 | $8.77 | -$200.61 | −95.81% |
| Q4 2018 | 2018-12-31 | $10.37 | -$15.22 | −59.47% |
| Q3 2018 | 2018-09-30 | $170.17 | -$201.22 | −54.18% |
| Q2 2018 | 2018-06-30 | $183.01 | -$223.70 | −55.00% |
| Q1 2018 | 2018-03-31 | $209.38 | -$237.46 | −53.14% |
| Q4 2017 | 2017-12-31 | $25.60 | -$467.49 | −94.81% |
| Q3 2017 | 2017-09-30 | $371.39 | -$108.64 | −22.63% |
| Q2 2017 | 2017-06-30 | $406.70 | -$121.97 | −23.07% |
| Q1 2017 | 2017-03-31 | $446.84 | -$142.88 | −24.23% |
| Q4 2016 | 2016-12-31 | $493.08 | -$165.06 | −25.08% |
| Q3 2016 | 2016-09-30 | $480.03 | -$243.11 | −33.62% |
| Q2 2016 | 2016-06-30 | $528.67 | -$257.09 | −32.72% |
| Q1 2016 | 2016-03-31 | $589.72 | -$264.04 | −30.93% |
| Q4 2015 | 2015-12-31 | $658.14 | $129.23 | +24.43% |
| Q3 2015 | 2015-09-30 | $723.14 | $123.94 | +20.68% |
| Q2 2015 | 2015-06-30 | $785.76 | $121.31 | +18.26% |
| Q1 2015 | 2015-03-31 | $853.76 | $122.56 | +16.76% |
| Q4 2014 | 2014-12-31 | $528.91 | -$273.31 | −34.07% |
| Q3 2014 | 2014-09-30 | $599.20 | $166.54 | +38.49% |
| Q2 2014 | 2014-06-30 | $664.45 | $174.83 | +35.71% |
| Q1 2014 | 2014-03-31 | $731.20 | $191.53 | +35.49% |
| Q4 2013 | 2013-12-31 | $802.22 | $469.06 | +140.79% |
| Q3 2013 | 2013-09-30 | $432.66 | $97.56 | +29.11% |
| Q2 2013 | 2013-06-30 | $489.62 | $129.34 | +35.90% |
| Q1 2013 | 2013-03-31 | $539.67 | $128.45 | +31.24% |
| Q4 2012 | 2012-12-31 | $333.16 | -$14.85 | −4.27% |
| Q3 2012 | 2012-09-30 | $335.10 | -$74.02 | −18.09% |
| Q2 2012 | 2012-06-30 | $360.28 | -$106.30 | −22.78% |
| Q1 2012 | 2012-03-31 | $411.23 | — | — |
| Q4 2011 | 2011-12-31 | $348.01 | -$177.59 | −33.79% |
| Q3 2011 | 2011-09-30 | $409.12 | — | — |
| Q2 2011 | 2011-06-30 | $466.58 | — | — |
| Q4 2010 | 2010-12-31 | $525.59 | — | — |
Celldex Therapeutics book value per share trends
Over the last five fiscal years, Celldex Therapeutics's book value per share increased from $5.29 to $7.92, a change of $2.64. The latest reported quarter, Q2 2026, shows $9.10.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Celldex Therapeutics source filings ↗